Blocking Leukocyte Migration and Inflammation with Antibodies
- Detailed Technology Description
- This invention employs antibodies to inhibit the migration of leukocytes in inflammatory processes.
- Others
-
US Patent Nos. 7,223,395 and 8,088,382
CD99 is a key mediator of the transendothelial migration of neutrophils.
J Immunol. 2007 Jan 15;178(2):1136-43.
CD99 plays a major role in the migration of monocytes through endothelial
junctions. Nat Immunol. 2002 Feb;3(2):143-50.
Murine CD99L2 is a cell adhesion molecule involved in the inflammatory response.
Cell Communication & Adhesion 2008 14:227-237
- *Abstract
-
Transendothelial migration (TEM) is the process by which leukocytes migrate out of the circulatory system and become irreversibly committed to entering the inflamed tissue. This process is promoted by interactions between adhesion molecules on the surface of the leukocytes and of the endothelial cells that line the blood vessels.
The inventors have discovered that two structurally related transmembrane proteins, namely CD99 and CD99L2, play a major, unexpected role in TEM. They showed that CD99 and CD99L2 are expressed on the surface of both leukocytes and endothelial cells where they mediate TEM of leukocytes through homophilic interactions.
The investigators generated monoclonal antibodies against human CD99 that blocked TEM by more than 90% in vitro. Antibodies against murine CD99 or CD99L2 reduce inflammation in a peritonitis inflammation model in vivo.
PotentialApplications
Antibody therapy for chronic conditions such as arthritis, psoriasis and other inflammatory or auto-immune diseases.
Advantage
An antibody based therapy for inflammation that does not interfere with the immune response against infections
- *Licensing
- Dan-Oscar Antsonda429@cornell.edu212-746-1297
- Country/Region
- USA
